On Tuesday, Gol Linhas Aereas Inteligentes SA (ADR) (NYSE:GOL)’s shares inclined 2.01%, and closed at $2.54, as Gol Linhas Aereas Inteligentes (GOL), the largest low-cost and best-fare airline in Latin America, informs its shareholders and the market in general that it was the leader in punctuality in the first quarter of 2015, with an index of 94.13%, according to data from Infraero (Brazilian Airport Infrastructure Corporation) on the domestic market. In March, the Corporation’s index reached 96.72%, with more than 23,000 domestic flights in the period.
This result reinforces GOL’s commitment to punctuality and customer satisfaction. For a year, the Corporation has been informing passengers about the punctuality of their flights through voice messages inside the aircraft and has been investing in other fronts to ensure greater speed and convenience during the trip. These comprise services accessible via mobile phone, such as flight status consultation, ticket purchases, check-in, seat selection, ticket anticipation and cancellation.
Gol Linhas Aéreas Inteligentes S.A. provides regular and non-regular air transportation services for passengers, cargoes, and mailbags in Brazil and internationally. It operates in two segments, Flight Transportation and Smiles Loyalty Program. The company operates a fleet of 150 aircraft, which includes 96 aircraft under operating leases and 46 aircraft under finance leases. It also develops and manages its own or third party’s customer loyalty program.
Rio Tinto plc (ADR) (NYSE:RIO)’s shares raised 1.92%, and settled at $42.48, during the last trading session on Tuesday, as Rio Tinto (RIO), will gift its 19.1 per cent shareholding in Northern Dynasty Minerals Ltd (Northern Dynasty), owner of the Pebble Project, to two local Alaskan charitable foundations. The decision follows the planned review declared last year of Rio Tinto’s interest in Northern Dynasty which concluded the Pebble Project does not fit with Rio Tinto’s strategy.
The shares in Northern Dynasty will be divided equally between the Alaska Community Foundation to fund educational and vocational training and the Bristol Bay Native Corporation Education Foundation, which supports educational and cultural programmers in the region.
Preceding to the gift, Rio Tinto, through Rio Tinto Fer et Titane Inc., an indirect wholly-owned partner of Rio Tinto plc, owned 18,145,845 ordinary shares of Northern Dynasty.
Rio Tinto plc, a mining and metals corporation, finds, mines, and processes mineral resources. The corporation mines and produces aluminum products, counting bauxite, alumina, and aluminum; copper, gold, silver, and molybdenum, in addition to nickel; diamonds, titanium dioxide feedstocks, borates, and salt, in addition to high purity iron, metal powders, zircon, and rutile; thermal coal, coking or metallurgical coal, and uranium; and iron ore.
At the end of Tuesday’s trade, Seagate Technology PLC (NASDAQ:STX)’s shares picked up 1.92%, and closed at $53.75, as Seagate Technology (STX), declared that its iconic Rugged Thunderbolt™ storage solution will be accessible in a 1 TB SSD capacity. With double the storage, the new LaCie® Rugged is just as portable with no size or weight raise contrast to the 500 GB offering. Plus, it still features the lightning-fast transfer rates of Thunderbolt and is tough in the field with shock, dust and water resistance.
The LaCie Rugged delivers speeds of up to 387 MB/s* – three times faster than a standard mobile hard drive**. With these speeds, creative professionals can transfer 100 GB in less than five minutes. The LaCie Rugged even provides enough bandwidth to review and edit photos or video in the field. With a laptop and a LaCie Rugged, a photographer or videographer has everything they need to back up footage or complete a project on location. This time savings and convenience is key for field-based professionals.
Seagate Technology Public Limited Corporation: designs, manufactures, and sells electronic data storage products in the Asia Pacific, the Americas, and EMEA countries. The corporation provides hard disk drives, solid state hybrid drives, and solid state drives that are designed for enterprise servers and storage systems in mission critical and nearline applications; for client compute applications comprising desktop and mobile computing; and for client non-compute applications, such as digital video recorders, personal data backup systems, portable external storage systems, and digital media systems.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), ended its Tuesday’s trading session with 1.88% gained, and closed at $120.47, formerly on March 23, Vertex Pharmaceuticals (VRTX), declared data from a 12-week Phase 2 study evaluating VX-661 in combination with ivacaftor in 39 people with CF ages 18 and older who have two copies of the F508del mutation. The study evaluated two doses of VX-661 (100 mg once daily or 50 mg every 12 hours) in combination with ivacaftor (150 mg every 12 hours). The primary endpoint of the study was safety. The study showed that the combination regimen was generally well tolerated, and all patients accomplished 12 weeks of treatment. The most ordinary adverse events were pulmonary exacerbation, which occurred in 38 percent of all patients who received VX-661 and 44 percent of those who received placebo, and cough, which occurred in 33 percent of all patients who received VX-661 and 39 percent of those who received placebo.
Secondary endpoints evaluated the effect of the combination on lung function (percent predicted forced expiratory volume in one second; ppFEV1), and the mean within-group absolute improvement from baseline in ppFEV1 for those who received 100 mg of VX-661 in combination with ivacaftor (n=15) was 4.4 (p=0.009) and 3.0 (p=0.026) percentage points at week 4 and through 12 weeks of treatment, respectively. Comprising with preceding Phase 2 studies that evaluated 4 weeks of treatment with VX-661 in combination with ivacaftor, this study showed a rapid improvement in lung function within four weeks of treatment, and after patients accomplished treatment, lung function returned to baseline.
Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. The corporation focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF); and advancing its research and early-stage development programs. It markets KALYDECO (ivacaftor) to treat patients of six years of age and older with CF who have the mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene in the United States, Australia, Canada, and the European Union.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
